Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against streptococcus mitis/ oralis in an ex vivo simulated endocarditis vegetation model
dc.contributor.author | Kebriaei, Razieh | |
dc.contributor.author | Rice, Seth A. | |
dc.contributor.author | Stamper, Kyle | |
dc.contributor.author | Seepersaud, Ravin | |
dc.contributor.author | García-De-La-Mària, Cristina | |
dc.contributor.author | Mishra, Nagendra Nath | |
dc.contributor.author | Miró, José Mª | |
dc.contributor.author | Arias, César A. | |
dc.contributor.author | Tran, Truc T | |
dc.contributor.author | Sullam, Paul M. | |
dc.contributor.author | Bayer, Arnold | |
dc.contributor.author | Rybak, Michael Joseph | |
dc.date.accessioned | 2020-05-08T00:02:31Z | |
dc.date.available | 2020-05-08T00:02:31Z | |
dc.date.issued | 2019 | |
dc.description.abstractenglish | T The viridans group streptococci (VGS) are a heterogeneous group of organisms which are important components of the normal human oral flora. Among the VGS, the Streptococcus mitis/oralis subgroup is one of the most common causes of infective endocarditis (IE). Daptomycin (DAP) is a potential alternative therapeutic option for invasive S. mitis infections, given high rates of -lactam resistance and vancomycin tolerance in such strains. However, the ability of these strains to rapidly evolve high-level and durable DAP resistance (DAP-R) is problematic. Recent data suggest that combination DAP--lactam therapy circumvents this issue. Humansimulated dose-escalating DAP-alone dose regimens (6, 8, 10, or 12 mg/kg/day times 4 days) versus DAP (6 mg/kg/day) plus ceftriaxone (CRO) (2 g once daily times 4 days or 0.5 g, single dose) were assessed against two prototypical DAP-susceptible (DAP-S) S. mitis/oralis strains (SF100 and 351), as measured by a pharmacokinetic/ pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs). No DAP-alone regimen was effective, with regrowth of high-level DAP-R isolates observed for both strains over 96-h exposures. Combinations of DAP-CRO with either single- or multidose regimens yielded significant reductions in log10 CFU/g amounts within SEVs for both strains (6 log10 CFU/g) within 24 h. In addition, no DAP-R strains were detected in either DAP-CRO combination regimens over the 96-h exposure. In contrast to prior in vitro studies, no perturbations in two key cardiolipin biosynthetic genes (cdsA and pgsA) were identified in DAP-R SEV isolates emerging from strain 351, despite defective phospholipid production. The combination of DAP-CRO warrants further investigation for treatment of IE due to S. mitis/oralis | eng |
dc.format.mimetype | application/pdf | |
dc.identifier.doi | https://doi.org/10.1128/AAC.00386-19 | |
dc.identifier.issn | 1098-6596 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12495/2509 | |
dc.language.iso | eng | |
dc.publisher | American Society for Microbiology | spa |
dc.publisher.journal | Antimicrobial agents and chemotherapy | spa |
dc.relation.ispartofseries | Antimicrobial agents and chemotherapy, 1098-6596, Vol. 63, Nro. 6, 2019, p. e00386-19 | spa |
dc.relation.uri | https://aac.asm.org/content/63/6/e00386-19.long | |
dc.rights.creativecommons | 2019 | |
dc.rights.local | Acceso cerrado | spa |
dc.subject.armarc | Ceftriaxone | spa |
dc.subject.armarc | Daptomycin | spa |
dc.subject.armarc | SEVs | spa |
dc.subject.decs | Estreptococos viridans | spa |
dc.subject.decs | Endocarditis bacteriana | spa |
dc.subject.decs | Resistencia betalactámica | spa |
dc.title | Daptomycin dose-ranging evaluation with single-dose versus multidose ceftriaxone combinations against streptococcus mitis/ oralis in an ex vivo simulated endocarditis vegetation model | spa |
dc.type | article | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | |
dc.type.local | artículo | spa |
Archivos
Bloque original
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- Kebriaei, R., Rice, S.A., Stamper, K.C., Seepersaud, R., Garcia-de-la-Maria, C., Mishra, N.N., Miro, J.M., Arias, C.A., Tran, T.T., Sullam, P.M. and Bayer, A.S., 2019.pdf
- Tamaño:
- 1.42 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 1.71 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: